ImmuCell Commences Manufacture of Nisin Necessary for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ImmuCell Commences Manufacture of Nisin Necessary for Approval of Mast Out(R)

PORTLAND, ME--(Marketwired - Jul 9, 2014) - ImmuCell Corporation ( NASDAQ : ICCC ) a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has completed modifications to its manufacturing facility to produce pharmaceutical-grade Nisin, the active ingredient in its Mast Out ® product, to address subclinical mastitis in lactating dairy cows.

ImmuCell (the Company) will commence validation and testing of the new facility and processing equipment to complete the manufacturing requirements of the New Animal Drug Application (NADA) submission to the Food and Drug Administration (FDA). Once this data has been compiled, the Company expects to make its first submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section to the FDA around the end of calendar year 2014. At the same time, Company scientists are working with the FDA to transfer the analytical method to detect Nisin in milk to an FDA laboratory. Once this method is successfully transferred, the Company expects to receive the Human Food Safety Technical Section Complete Letter from the FDA. These are the final two steps in the NADA process, as Mast Out ® has previously received the following from the FDA:

  • The Environmental Impact Technical Section Complete Letter;
  • The Target Animal Safety Technical Section Complete Letter;
  • The Effectiveness Technical Section Complete Letter; and
  • A zero milk discard and zero meat withhold claim.

The Company anticipates two, six-month reviews of the CMC Technical Section submission by the FDA during 2015, setting up potential NADA approval from the FDA during 2016. This would allow test marketing of Mast Out ® in 2016.

Michael F. Brigham, President and CEO of ImmuCell, commented, "We are pleased with the progress achieved during the first half of fiscal 2014 in completing the necessary modifications to our manufacturing facilities on time and on budget. We will now begin to utilize the newly installed equipment and space to demonstrate to the FDA our ability to effectively produce pharmaceutical-grade Nisin while verifying process yields."

Mastitis is considered the costliest disease to the U.S. dairy industry and major dairy producing regions of the world. Annual losses are presently estimated to be upwards of $2 Billion in the United States alone. These losses are comprised of reduced milk production, discarded milk, replacement animals, labor, drug treatments and veterinarian services. Mastitis refers to an inflammation of the udder, most commonly caused by a bacterial infection. This infection is commonly treated with traditional antibiotics. Mast Out ® , an intramammary infusion product containing Nisin, is under development as an alternative to traditional antibiotics for the treatment of subclinical mastitis in lactating cows. The safety profile of Nisin may allow for the use of Mast Out ® in the United States without "milk discard" or "meat withhold" requirements.

In late 2013, the Company announced a $3 Million capital improvement investment, allocating approximately half of this total to build out modifications of its facility and acquire equipment necessary to produce pharmaceutical-grade Nisin for Mast Out ® . The remaining amount has been allocated to a 7,100 square foot facility addition intended to increase production capacity for current products, maintain compliance with current Good Manufacturing Practice (cGMP) regulations in all operations and integrate the production of pharmaceutical-grade Nisin. The Company is preparing to break ground on this second project during the third quarter of 2014.

About ImmuCell ImmuCell Corporation's ( NASDAQ : ICCC ) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant immediate immunity to newborn dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at our web-site, ( http://www.immucell.com ).

Safe Harbor Statement: This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; the future adequacy of our working capital and the availability of third party financing; the outcome of pending or anticipated applications for future regulatory approvals; factors that may affect the dairy and beef industries and future demand for our products; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, the uncertainties associated with product development, pharmaceutical-grade Nisin manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors.

Contact: Michael F. Brigham President and CEO (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 274

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 308

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 252

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
ss="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles